Impact of anemia on the survival of patients undergoing radical cystectomy for bladder cancer
| Autor: | M. Barquero-López, A. Ferran-Carpintero, J. Prats-López, N. Hannaoui-Hadi, Á. Prera-Vilaseca, J. Muñoz-Rodríguez, D. García-Rojo, A. Domínguez-García, T. Bonfill-Abella, E. Gallardo-Díaz |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Chemotherapy
medicine.medical_specialty Blood management Bladder cancer business.industry Anemia medicine.medical_treatment Prehabilitation 030232 urology & nephrology Urology General Medicine medicine.disease Cystectomy 03 medical and health sciences 0302 clinical medicine Ectasia Medicine business Who classification |
| Zdroj: | Actas Urológicas Españolas (English Edition). 44:489-496 |
| ISSN: | 2173-5786 |
| DOI: | 10.1016/j.acuroe.2020.08.005 |
| Popis: | Objective To evaluate the prevalence of preoperative anemia and its effect on oncological outcomes in patients undergoing radical cystectomy (RC) due to bladder cancer. Materials and method Retrospective single-center study with 176 RCs between May 2008 and July 2018. Anemia was defined according to the WHO classification (male Results Overall, 89 (50.6%) patients had preoperative anemia, and 44 of them (49.4%) received neoadjuvant chemotherapy. Anemic patients resulted in higher rates of ASA (ASA > 2: 54.6 vs. 27.5%; P = .003), ectasia rate previous to RC (41.6 vs. 19.5%; P = .002), treatment with neoadjuvant chemotherapy (49.4 vs. 19.5%; P 2 and N ≥ 1 were independently associated with overall mortality. Conclusion Preoperative anemia was common in patients undergoing RC for bladder cancer, and it is related with a worse cancer prognosis. Anemia is a preoperative modifiable factor; we believe that the implementation of Patient Blood Management programs during prehabilitation may have a relevant role in improving the oncological outcomes in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect